Get the Stockscreener App
438.40
0.71%
-3.12
After Hours:
438.40
Vertex Pharmaceuticals Inc stock is traded at $438.40, with a volume of 1.08M.
It is down -0.71% in the last 24 hours and up +9.78% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$441.52
Open:
$443.56
24h Volume:
1.08M
Relative Volume:
0.75
Market Cap:
$113.67B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
-220.30
EPS:
-1.99
Net Cash Flow:
$-1.35B
1W Performance:
-0.30%
1M Performance:
+9.78%
6M Performance:
-12.78%
1Y Performance:
-1.72%
1-Day Range:
$435.00
$444.27
1-Week Range:
$430.81
$447.72
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’ - Insider Monkey
March 14th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex downgraded at Wells Fargo on limited near-term upside - Seeking Alpha
Vertex Awaits FDA Verdict on Landmark Non-Opioid Pain Drug - BioSpace
Cargo to lay off staff after CAR-T data show safety concerns - STAT
Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83% - Yahoo Finance
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings) - Benzinga
Wells Fargo Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Price Target is $460 - Marketscreener.com
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com
Swedbank AB Reduces Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Foster Victor Wealth Advisors LLC Buys 3,062 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Forsta AP Fonden Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal? - PharmaVoice
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lowered by Robeco Institutional Asset Management B.V. - MarketBeat
Williams & Novak LLC Takes $277,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
YHB Investment Advisors Inc. Acquires New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Pacer Advisors Inc. Has $15.63 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Blue Trust Inc. - MarketBeat
RFG Advisory LLC Sells 1,001 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Approvals The US FDA Is Not Talking About: A Communication Freeze Calendar - News & Insights
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Griffin Asset Management Inc. Sells 581 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Slow Capital Inc. - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by KBC Group NV - MarketBeat
Vertex is hoping for 'historic' non-opioid painkiller approval. It might not be a straightforward blockbuster. - The Business Journals
Piper Sandler Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipeline stock growth - Investing.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $533.00 by Analysts at Piper Sandler - MarketBeat
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Lifted by Parsons Capital Management Inc. RI - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Heirloom Wealth Management - MarketBeat
Vertex Pharmaceuticals Sets Q4 2024 Earnings Call for February 10 - StockTitan
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 - Business Wire
Marshall Financial Group LLC Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
First Citizens Bank & Trust Co. Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SG Americas Securities LLC Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (VRTX) Expected to Announce Earnings on Monday - MarketBeat
Top 10 most anticipated drug launches of 2025 - FiercePharma
Is Vertex Pharmaceuticals Stock a Buy in 2025? - sharewise
Moody Lynn & Lieberson LLC Sells 7,984 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Toth Financial Advisory Corp Sells 1,320 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Fifth Third Bancorp - MarketBeat
Harel Insurance Investments & Financial Services Ltd. Lowers Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. - The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Linden Thomas Advisory Services LLC Has $3 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria
Brighton Jones LLC Boosts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):